ELTX · Elicio Therapeutics, Inc. · Share Buybacks
Substantial doubt about the company's ability to continue as a going concern.
“We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Share-repurchase activity from the company's own XBRL filings — cash spent on equity repurchases (common and preferred combined, as reported) per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-03-16 | — | $100,000,000 | — | — | 8-K , filed 2026-03-16 |
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2024-12-31 | $0 | 10-K, filed 2025-03-31 |
| 2023-12-31 | $150,000 | 10-K, filed 2025-03-31 |
| 2022-12-31 | $0 | 10-K, filed 2024-03-29 |